A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared with Pembrolizumab in Patients with Resectable Stage III and IV Melanoma R3767-ONC-2208
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
November 20, 2024
End Date
November 16, 2029
Administered By
Duke Cancer Institute
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
November 20, 2024
End Date
November 16, 2029